Management of anastomotic leakage in upper gastrointestinal tract after oncologic surgery: Role of fully covered metallic stents

Table 1 Clinical characteristics

Variable	n (%)
Sex
Male	56 (80.0)
Female	14 (20.0)
Age (median, range)	65.5 (39.0-87.0)
Tumor location
Esophageal	18 (25.7)
Esophagogastric junction	33 (47.1)
Gastric	19 (27.1)
Histology
Adenocarcinoma	51 (72.9)
Squamous cell carcinoma	15 (21.4)
High grade dysplasia	2 (2.9)
GIST	2 (2.9)
Neoadjuvant treatment
None	22 (31.4)
Chemotherapy	13 (18.6)
Chemoradiotherapy	35 (50.0)
Surgery
Esophagectomy	37 (52.9)
McKeown	16 (22.9)
Ivor Lewis	21 (30)
Gastrectomy	31 (44.3)
Total	30 (42.9)
Atypical	1 (1.4)
Merendino surgery	2 (2.9)

GIST: Gastrointestinal stromal tumor.

Table 2 Fully covered self-expandable metallic stents treatment

Variable	n (%)
Defect size (mm)
< 10	44 (62.9)
10-20	12 (17.1)
> 20	14 (20)
Location (cm)
< 25	25 (35.7)
25-30	15 (21.4)
> 30	30 (42.9)
CRP at diagnosis	312.1 ± 116.4
Predicted probability of stent success (9)
< 50% (score < 130)	6 (8.5)
50%-70% (score 111-170)	39 (55.7)
> 70% (score > 170)	25 (35.7)
Stents/patient
1	46 (65.7)
2	19 (27.1)
3	1 (1.4)
4	4 (5.7)

CRP: C-reactive protein.